BioArctic AB (publ) (BRCTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioArctic AB (publ) (BRCTF) trades at $35.00 with AI Score 51/100 (Grade B). BioArctic AB (publ) is a Swedish biopharmaceutical company focused on developing innovative treatments for central nervous system disorders. Market cap: $3.11B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for BRCTF: BRCTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRCTF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BRCTF: 4/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →BioArctic AB (publ) (BRCTF) Healthcare & Pipeline Overview
BioArctic AB (publ) is a Swedish biotechnology firm specializing in biological drugs for central nervous system disorders, including Alzheimer's and Parkinson's disease. The company's innovative antibody technology platform and strategic collaborations with Eisai and AbbVie position it as a key player in neurodegenerative disease therapeutics.
What Is the Investment Thesis for BRCTF?
BioArctic presents a notable research candidate due to its focus on neurodegenerative diseases with high unmet needs and its advanced clinical pipeline. The primary value driver is Lecanemab, currently in Phase 3 trials for Alzheimer's disease, with potential for significant revenue upon regulatory approval. The company's strong partnerships with Eisai and AbbVie provide financial and development support. Key catalysts include the readout of Phase 3 Lecanemab data and advancement of other pipeline programs. However, the investment carries risks associated with clinical trial outcomes, regulatory hurdles, and competition from other companies developing Alzheimer's therapies. BioArctic's high profit margin of 51.1% and ROE of 71.4% suggest efficient operations, but the high D/E ratio of 2.24 warrants monitoring.
Based on FMP financials and quantitative analysis
BRCTF Key Highlights
- Market capitalization of $3.11B reflects investor confidence in BioArctic's pipeline and Alzheimer's disease program.
- Profit margin of 51.1% indicates strong profitability and efficient cost management.
- Gross margin of 97.0% demonstrates the high value of BioArctic's pharmaceutical products.
- Return on Equity (ROE) of 71.4% signifies effective utilization of shareholder equity to generate profits.
- Debt-to-Equity ratio of 2.24 suggests a relatively leveraged capital structure, requiring careful monitoring.
Who Are BRCTF's Competitors?
BRCTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIIB Biogen Inc. | $212.58 | -1.64% | $31.39B | 78 |
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| RHHBY Roche Holding AG | $51.62 | -2.68% | $332.48B | 61 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRCTF's Key Strengths?
- Innovative antibody technology platform.
- Strong focus on neurodegenerative diseases.
- Strategic collaborations with Eisai and AbbVie.
- Advanced clinical pipeline with Lecanemab in Phase 3.
What Are BRCTF's Weaknesses?
- Reliance on partnerships for drug development and commercialization.
- High R&D costs and long development timelines.
- Concentration of pipeline on Alzheimer's disease.
- Limited commercial infrastructure.
What Could Drive BRCTF Stock Higher?
- Phase 3 clinical trial results for Lecanemab in Alzheimer's disease (expected in 2026).
- Advancement of Exidavnemab into Phase 3 clinical trials for Parkinson's disease (timeline dependent on Phase 2 results).
- Continued progress in research and development of novel antibody therapeutics.
- Potential for new strategic collaborations or partnerships to expand the pipeline.
What Are the Key Risks for BRCTF?
- Clinical trial failures for Lecanemab or other pipeline programs.
- Regulatory delays or rejection of drug approvals.
- Competition from other companies developing Alzheimer's therapies.
- High R&D costs and long development timelines.
- Reliance on partnerships for drug development and commercialization.
What Are the Growth Opportunities for BRCTF?
- Expansion of Lecanemab into new indications: Beyond its current focus on early Alzheimer's disease, Lecanemab could be investigated for potential efficacy in treating other forms of dementia or related neurodegenerative conditions. This would broaden the addressable patient population and extend the drug's commercial lifespan. The market for dementia therapeutics is projected to reach $13.3 billion by 2028, presenting a significant growth opportunity for BioArctic.
- Advancement of Exidavnemab for Parkinson's Disease: Exidavnemab, currently in Phase 2 clinical trials, targets alpha-synuclein, a protein implicated in Parkinson's disease. Successful development and commercialization of Exidavnemab would diversify BioArctic's pipeline and establish a presence in the Parkinson's disease market, which is expected to reach $5.6 billion by 2027. Positive clinical data from Phase 2 trials would be a key catalyst for this growth opportunity.
- Development of Novel Antibody Therapeutics: BioArctic's technology platform enables the discovery and development of novel antibody therapeutics targeting various CNS disorders. Investing in R&D to expand the pipeline with innovative programs could yield future blockbuster drugs. The global market for antibody therapeutics is projected to reach $300 billion by 2025, highlighting the potential for significant returns on R&D investments.
- Geographic Expansion: While BioArctic is currently focused on collaborations with Eisai and AbbVie, expanding its geographic reach through partnerships or direct commercialization efforts in other regions, such as Asia and Latin America, could drive revenue growth. The increasing prevalence of neurodegenerative diseases in these regions presents a significant market opportunity. A strategic approach to geographic expansion could unlock substantial value for BioArctic.
- Strategic Collaborations and Acquisitions: BioArctic can pursue strategic collaborations with other biotechnology or pharmaceutical companies to accelerate the development and commercialization of its pipeline programs. Acquiring complementary technologies or companies could also enhance BioArctic's capabilities and expand its product portfolio. The biotechnology industry is characterized by frequent M&A activity, and BioArctic could leverage this trend to drive growth and innovation.
What Opportunities Does BRCTF Have?
- Expansion of Lecanemab into new indications.
- Advancement of Exidavnemab for Parkinson's disease.
- Development of novel antibody therapeutics.
- Geographic expansion into new markets.
What Threats Does BRCTF Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other companies developing Alzheimer's therapies.
- Patent expirations.
What Are BRCTF's Competitive Advantages?
- Proprietary antibody technology platform for developing novel biological drugs.
- Strong intellectual property protection for its drug candidates.
- Strategic collaborations with major pharmaceutical companies like Eisai and AbbVie.
- Expertise in developing drugs for neurodegenerative diseases with high unmet needs.
What Does BRCTF Do?
BioArctic AB (publ), founded in 2000 and based in Stockholm, Sweden, is a biopharmaceutical company dedicated to developing innovative biological drugs for patients suffering from central nervous system (CNS) disorders. The company focuses on addressing high unmet medical needs through the research and development of novel antibodies. BioArctic's primary therapeutic focus lies in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other CNS-related conditions. Their core technology platform enables the development of therapeutic monoclonal antibodies designed to target the underlying causes of these debilitating diseases. BioArctic's lead product candidate is Lecanemab, an antibody targeting amyloid-beta protofibrils, a key pathological hallmark of Alzheimer's disease. Lecanemab is currently in Phase 3 clinical trials in collaboration with Eisai. The company's pipeline also includes Exidavnemab, in Phase 2 clinical trials, and other preclinical and discovery-stage programs targeting various CNS disorders. BioArctic has established research collaboration agreements with major pharmaceutical companies like Eisai and AbbVie to advance its research and development efforts. Formerly known as BioArctic Neuroscience AB, the company changed its name to BioArctic AB (publ) in 2016, reflecting its evolution and strategic focus.
What Products and Services Does BRCTF Offer?
- Develops biological drugs for central nervous system disorders.
- Researches and develops innovative antibodies to address unmet medical needs.
- Focuses on neurodegenerative disorders like Alzheimer's and Parkinson's disease.
- Utilizes a technology platform to develop therapeutic monoclonal antibodies.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with pharmaceutical companies like Eisai and AbbVie to advance drug development.
How Does BRCTF Make Money?
- Develops and patents novel biological drugs targeting CNS disorders.
- Out-licenses or co-develops its drug candidates with larger pharmaceutical companies.
- Generates revenue through upfront payments, milestone payments, and royalties on sales of partnered drugs.
- Reinvests revenue into research and development to expand its pipeline.
What Industry Does BRCTF Operate In?
BioArctic operates in the biotechnology industry, specifically focusing on neurodegenerative diseases. The market for Alzheimer's disease therapeutics is substantial and growing, driven by an aging global population and increasing prevalence of the disease. Competition is intense, with major pharmaceutical companies like Roche, Biogen, and Eli Lilly also developing Alzheimer's treatments. BioArctic's collaboration with Eisai provides a competitive advantage, leveraging Eisai's expertise in drug development and commercialization. The industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny.
Who Are BRCTF's Key Customers?
- Patients suffering from central nervous system disorders, such as Alzheimer's and Parkinson's disease.
- Pharmaceutical companies that partner with BioArctic to develop and commercialize its drugs.
- Healthcare providers who prescribe BioArctic's drugs to their patients.
- Payers (insurance companies and government healthcare systems) that reimburse for BioArctic's drugs.
BioArctic AB (publ) Financial Trajectory
BioArctic AB (publ) (BRCTF) reported $437.6M in revenue for Q1 2026, reflecting 138.4% growth compared to the prior quarter. The company recorded net income of $212.4M, with diluted EPS of $2.39. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, BRCTF averaged $0.60 in diluted EPS.
Company Profile
BioArctic AB (publ) operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Gunilla Osswald. BRCTF has traded publicly since 2022.
How BioArctic AB (publ) Is Valued
BioArctic AB (publ) carries a market capitalization of $3.11B, placing it in the mid-cap category. Relative to its peer group, BRCTF's quantitative score of 51/100 is below the peer average of 79/100.
ROE 10%Key Financial Metrics
Return on equity for BioArctic AB (publ) stands at 10.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.0%, showing how much profit it generates from its asset base. BRCTF trades at a trailing price-to-earnings ratio of 127.78, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
BioArctic AB (publ)'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 39.27 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project BioArctic AB (publ) revenue of about $1.14B for fiscal 2026, with EPS near $2.99. The estimate reflects 4 contributing analysts.
BRCTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that key stakeholders believe in the value of upcoming developments.
- Community sentiment has shown a positive shift as discussions around innovative therapies have gained traction, highlighting investor optimism.
- Market perception has improved with recent announcements regarding partnerships, which could enhance BioArctic's research capabilities and market reach.
- The growing interest in neurodegenerative disease treatments aligns with BioArctic's focus, positioning the company favorably within a crucial sector.
Bear Case
- Concerns over the competitive landscape for neurodegenerative therapies persist, as larger pharmaceutical companies continue to dominate the market.
- Recent community discussions have highlighted skepticism regarding the timeline for product development, raising doubts about potential revenue generation.
- Regulatory hurdles remain a significant concern, with past delays in approvals impacting investor confidence and market performance.
- Overall market volatility has led to cautious sentiment, with some investors wary of the biotech sector's inherent risks and uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $438M | $212M | $2.39 |
| Q4 2025 | $184M | -$9M | -$0.10 |
| Q3 2025 | $133M | -$87M | -$0.98 |
| Q2 2025 | $392M | $97M | $1.09 |
Based on FMP financials and quantitative analysis
BRCTF Latest News
No recent news available for BRCTF.
BRCTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRCTF.
Price Targets
Wall Street price target analysis for BRCTF.
BRCTF MoonshotScore
What does this score mean?
The MoonshotScore rates BRCTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
BRCTF OTC Market Information
The OTC Other tier, where BRCTF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure, may not meet minimum listing standards, and can be subject to greater price volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and less stringent listing criteria, leading to increased risk for investors. These companies may be newly formed, in early stages of development, or have difficulty meeting the requirements of larger exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Wider bid-ask spreads can increase transaction costs.
- Potential for fraud or manipulation is higher on the OTC market.
- OTC stocks may be subject to reverse splits or other corporate actions that can negatively impact shareholders.
- Verify the company's registration and regulatory filings.
- Review the company's financials, if available.
- Assess the company's management team and track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's capital structure and debt levels.
- Monitor news and announcements related to the company.
- Consult with a financial advisor before investing.
- Established research collaborations with reputable pharmaceutical companies like Eisai and AbbVie.
- Advanced clinical pipeline with Lecanemab in Phase 3 trials.
- Focus on addressing high unmet medical needs in neurodegenerative diseases.
- Incorporated in 2000, indicating a history of operations.
BioArctic AB (publ) Healthcare Stock: Key Questions Answered
What does BioArctic AB (publ) do?
BioArctic AB (publ) is a Swedish biopharmaceutical company focused on developing innovative biological drugs for patients with central nervous system (CNS) disorders, particularly neurodegenerative diseases like Alzheimer's and Parkinson's disease. The company's core expertise lies in developing therapeutic monoclonal antibodies that target the underlying causes of these diseases. BioArctic's lead product candidate, Lecanemab, is currently in Phase 3 clinical trials for Alzheimer's disease, being developed in collaboration with Eisai. The company also has other preclinical and discovery-stage programs targeting various CNS disorders, aiming to address significant unmet medical needs in this therapeutic area.
What do analysts say about BRCTF stock?
Analyst coverage of BRCTF is limited due to its OTC listing and Swedish domicile. However, the company's prospects are closely tied to the success of Lecanemab in Alzheimer's disease. Positive Phase 3 trial results and regulatory approval would likely drive significant upside potential. Key valuation metrics to consider include the potential peak sales of Lecanemab and the royalty rates BioArctic receives from its partnership with Eisai. Investors should also monitor the progress of BioArctic's other pipeline programs and the overall competitive landscape in Alzheimer's disease therapeutics. Analyst opinions will likely coalesce upon further clinical and regulatory milestones.
What are the main risks for BRCTF?
The primary risks for BioArctic AB (publ) revolve around the clinical development and regulatory approval of its drug candidates, particularly Lecanemab for Alzheimer's disease. Clinical trial failures, regulatory delays, or rejection of drug approvals could significantly impact the company's value. Competition from other companies developing Alzheimer's therapies also poses a risk. Furthermore, BioArctic relies on partnerships with larger pharmaceutical companies like Eisai and AbbVie for drug development and commercialization, which introduces dependence risk. The company's high R&D costs and long development timelines also present financial challenges, requiring careful management of resources and capital.
What are the key factors to evaluate for BRCTF?
BioArctic AB (publ) (BRCTF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does BRCTF data refresh on this page?
BRCTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BRCTF's recent stock price performance?
BioArctic AB (publ) (BRCTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative antibody technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRCTF overvalued or undervalued right now?
Valuing BioArctic AB (publ) (BRCTF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BRCTF?
Before investing in BioArctic AB (publ) (BRCTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Information based on available company filings and press releases.